AUTHOR=Ludueña Richard F. , Walss-Bass Consuelo , Portyanko Anna , Guo Jiayan , Yeh I-Tien 

TITLE=Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment

JOURNAL=Frontiers in Cell and Developmental Biology

VOLUME=10

YEAR=2022

URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2022.870088

DOI=10.3389/fcell.2022.870088

ISSN=2296-634X

ABSTRACT=<p>Microtubules are organelles that usually occur only in the cytosol. <xref ref-type="bibr" rid="B55">Walss et al. (1999)</xref> discovered the βII isotype of tubulin, complexed with <italic>α</italic>, in the nuclei of certain cultured cells, in non-microtubule form. When fluorescently labeled tubulins were microinjected into the cells, only <italic>αβ</italic>II appeared in the nucleus, and only after one cycle of nuclear disassembly and reassembly. It appeared as if <italic>αβ</italic>II does not cross the nuclear envelope but is trapped in the nucleus by the re-forming nuclear envelope in whose reassembly <italic>β</italic>II may be involved. <italic>β</italic>II is present in the cytoplasm and nuclei of many tumor cells. With some exceptions, normal tissues that expressed βII rarely had βII in their nuclei. It is possible that βII is involved in nuclear reassembly and then disappears from the nucleus. <xref ref-type="bibr" rid="B47">Ruksha et al. (2019)</xref> observed that patients whose colon cancer cells in the invasive front showed no βII had a median survival of about 5.5 years, which was more than halved if they had cytosolic <italic>β</italic>II and further lessened if they had nuclear <italic>β</italic>II, suggesting that the presence and location of <italic>β</italic>II in biopsies could be a useful prognostic indicator and also that <italic>β</italic>II may be involved in cancer progression. <xref ref-type="bibr" rid="B61">Yeh and Ludueña. (2004)</xref> observed that many tumors were surrounded by non-cancerous cells exhibiting cytosolic and nuclear <italic>β</italic>II, suggesting a signaling pathway that causes <italic>β</italic>II to be synthesized in nearby cells and localized to their nuclei. <italic>β</italic>II could be useful in cancer diagnosis, since the presence of <italic>β</italic>II in non-cancerous cells could indicate a nearby tumor. Investigation of this pathway might reveal novel targets for chemotherapy. Another possibility would be to combine <italic>αβ</italic>II with CRISPR-Cas9. This complex would likely enter the nucleus of a cancer cell and, if guided to the appropriate gene, might destroy the cancer cell or make it less aggressive; possible targets will be discussed here. The possibilities raised here about the utility of <italic>β</italic>II in cancer diagnosis, prognosis, biology and therapy may repay further investigation.</p>